The World Health Organization (WHO) published the 55th situation report for the multi-country outbreak of mpox virus (MPXV), which provides details on the global epidemiological situation for mpox, including an update in Africa.
All clades of MPXV continue to circulate in several countries.
On July 11, 2025, the WHO stated that only Türkiye has reported the detection of a new MPXV sub-clade since report #54, in a traveler from the Democratic Republic of the Congo (DRC).
In Africa, community transmission of clade Ib MPXV remains limited to 19 countries. Most countries with previous sporadic importations are currently not reporting active transmission of clade Ib MPXV.
As of July 8, 2025, the countries of Burundi, DRC, Ethiopia, Kenya, Malawi, Rwanda, South Sudan, Tanzania, Uganda, and Zambia are experiencing sustained human-to-human transmission of the virus.
Clade IIb MPXV continues to be reported in West Africa, while Central African countries report both clade Ia and clade Ib MPXV, and East African countries report clade Ib MPXV.
The WHO noted that, despite progress in response activities implemented through collaboration among governments, international partners, and communities, significant funding gaps are threatening the deployment of vaccines.
Approximately 724,000 MVA-BN (JYNNEOS) vaccine doses had been administered in 7 countries, out of the 1.9 million vaccine doses allocated to 13 countries, partly due to funding requirements for shipping to the countries.
Additionally, the DRC had received 1.55 million doses of the LC16m8 vaccine from a bilateral agreement.
In the United States, the JYNNEOS vaccine has become readily available at travel clinics and pharmacies and is recommended for specific international travelers.